**Table S1** The baseline characteristics of 129 patients with refractory cervical cancer and Cox multivariate analysis of their overall survival

|                                | No. of patients (%) | Univariate |               | Multivariate |             |
|--------------------------------|---------------------|------------|---------------|--------------|-------------|
|                                |                     |            | HR (95% CI)   | P            | HR (95% CI) | P          |
| Age, years                     |                     |            |               |              |             |
| <52                            | 69 (53.5%)          | 1.00       |               |              |             |
| ≥52                            | 60 (46.5%)          | 0.79 (0.36–1.73) | 0.58 |             |             |
| Tumor diameter                 |                     |            |               |              |             |
| <6 cm                          | 57 (44.2%)          | 1.00       |               |              |             |
| ≥6 cm                          | 72 (55.8%)          | 1.42 (0.67–3.0) | 0.36 |             |             |
| OTT                            |                     |            |               |              |             |
| <56 days                       | 61 (47.3%)          | 1.00       |               |              |             |
| ≥56 days                       | 68 (52.7%)          | 0.67 (0.31–1.44) | 0.31 |             |             |
| Treatment modalities           |                     |            |               |              |             |
| NACT+CCRT                      | 77 (59.7%)          | 1.00       |               |              |             |
| CCRT                           | 52 (40.3%)          | 0.51 (0.22–1.16) | 0.11 |             |             |
| Combined bevacizumab           |                     |            |               |              |             |
| Yes                            | 64 (49.6%)          | 1.00       |               | 1.00         | 1.00        |
| No                             | 65 (50.4%)          | 3.72 (1.27–10.93) | 0.017 | 3.72 (1.26–10.93) | 0.017 |
| Histology                      |                     |            |               |              |             |
| Squamous                       | 122 (94.6%)         | 1.000      |               |              |             |
| Others                         | 7 (5.4%)            | 0.045 (0.00–54.03) | 0.39 |             |             |
| FIGO stage                     |                     |            |               |              |             |
| IIB–IIIB                       | 40 (31%)            | 1.00       |               |              |             |
| IIIIC1                         | 40 (31%)            | 0.83 (0.53–1.76) | 0.37 |             |             |
| IIIIC2                         | 33 (25.6%)          | 0.52 (0.18–1.43) | 0.98 |             |             |
| IVB-Ln only                    | 10 (7.7%)           | 0.32 (0.09–1.53) | 0.12 |             |             |
| *Pelvic relapse (d >5 cm)      | 6 (4.7%)            | 0.517 (0.08–1.16) | 0.35 |             |             |
| Tumor response before BT       |                     |            |               |              |             |
| cCR                            | 72 (55.8%)          | 1.00       |               |              |             |
| Non-cCR                        | 57 (44.2%)          | 2.1 (0.96–4.59) | 0.053 | 0.45 (0.09–1.53) | 0.12 |

cCR, clinical complete response.